GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

ShareUK pharmaceutical giant, GSK said it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

British pharmaceutical company GSK has agreed to pay $2.3 billion to settle lawsuits alleging that its heart burn medication Zantac caused cancer. GSK has settled 80,000 Zantac lawsuit. Watch to know ...

GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...

GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before litigation started in summer 2022. The drugs group rose 5% or 77.5p to 1535 ...

GSK to resolve 93% of US state court Zantac product liability cases for up to $2.2 billion: London, UK Friday, October 11, 2024, 14:00 Hrs [IST] GSK plc announced that it has reac ...

European shares closed lower on Thursday, with defence and industrial stocks leading losses, after data showed U.S. inflation ...

Shares in GSK surged after the pharmaceuticals company announced a $2.2bn settlement to resolve approximately 80,000 Zantac lawsuits in the US. The company revealed that it had reached agreements with ...

Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...